introduction: several lines of evidence suggest that the factor xiii (fxiii) 100 g/t polymorphism may influence susceptibility to deep venous thromboembolism (dvt). to explore this hypothesis, we investigated whether this polymorphism is associated with the predisposition to dvt. we also predict the possible impact of residue substitution at codons 34 (val34leu) in a subunits of the fxiii coagu...

Although many epidemiologic studies have investigated the FXIII-A Val34Leu polymorphism and their associations with myocardial infarction (MI), definite conclusions can't be drawn. To clarify the effects of FXIII-A Val34Leu polymorphism on the risk of MI, a meta-analysis was performed. Related studies were identified from PubMed, Springer Link, Ovid, Chinese Wanfang Data Knowledge Service Platf...

OBJECTIVE Coagulation Factor XIII (FXIII) was previously shown by us to induce angiogenesis. The aim of this study was to elucidate the molecular events underlying the proangiogenic effects of activated FXIII (FXIIIa) on human umbilical vein endothelial cells (HUVECs). METHODS AND RESULTS As shown by coimmunoprecipitation studies, FXIIIa crosslinked alpha(v)beta3 with vascular endothelial gro...

Macular degenerations represent leading causes of central blindness or low vision in developed countries. Most of these severe visual disabilities are due to age-related macular degeneration (AMD) and pathologic myopia (PM), both of which are frequently complicated by subfoveal choroidal neovascularization (CNV). Photodynamic therapy with verteporfin (PDT-V) is still employed for CNV treatment ...

Multidisciplinary research from the last few decades has revealed that Factor XIII subunit A (FXIII-A) is not only involved in blood coagulation, but may have roles various diseases. Here, we aim to summarize data studies involving patients with mutations F13A1 gene, performed FXIII-A knock-out mice models, clinical and histological assessing correlations between diseases severity levels, as we...

While there are challenges to understanding more about bleeding disorders through research due to the orphan nature of disorders such as the congenital haemophilias, the challenge is even greater for the much less common group of clotting factor deficiencies, qualitative platelet disorders, and other rare clinical conditions, designated collectively as rare bleeding disorders (RBDs). For haemat...

Factor XIII (FXIII) is a zymogen that is converted into an active transglutaminase (FXIIIa) by the concerted action of thrombin and Ca2+. Its main task is to crosslink alpha-, and gamma-chains of fibrin and alpha2-plasmin inhibitor to fibrin. By this way FXIIIa strengthens fibrin and protects it from the prompt elimination by fibrinolytic system.The changes of FXIII level in thrombotic diseases...

BACKGROUND Hemodilution and consumption of coagulation factors during cardiopulmonary bypass has been suggested to contribute to bleeding complications after cardiac surgery. The aim was to describe the activity of individual coagulation factors after CABG in relation to hemodilution and postoperative bleeding. MATERIALS AND METHODS Plasma concentrations of fibrinogen and plasma activity of F...

The Val34Leu polymorphism in the A subunit of blood coagulation factor XIII (FXIII-A) is located in the activation peptide, just three amino acids upstream of the thrombin cleavage site. The Val-->Leu replacement accelerates the rate of the proteolytic activation of FXIII and it seems to provide protection against myocardial infarction. Methods available for the assessment of the FXIII-A Val34L...